Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: publications understanding treatment preferences patients kras pg12clc1 mk2 ��� mutated advanced non
… uptake. Real-World Insight: Imagine you have a novel treatment for a chronic disease. Early discussions with … product’s appeal. 2. Map Prescribing Pathways for Current Treatment Options Why it Matters: Understanding what competing drugs exist and how they are …
… will be presented at ADA's 84th Scientific Sessions. Preferences of people with type 2 diabetes for features of … Vass C , Poon JL, Gelsey FT, Pierce A, Mansfield C. Poster Preferences of people with type 1 diabetes for features of …
… management. At RTI, she has led a preference study understanding high risk population’s preference for a preventative treatment for lung cancer, and has been involved in several …
… citizen. Our objective is to clarify and quantify these treatment effects for the citizens of Europe.” The SIGMA …
… stated preference methods to measuring the benefit-risk preferences of patients and other health care decision-makers. She has been … the ISPOR FDA summit. She has over 50 peer-reviewed publications in journals that include The Patient, Value in …
… Selecting a time horizon Identifying current and projected treatment mix Estimating current and future drug costs … course offering applied learning techniques for novice and advanced modelers with outstanding instructors! This class …
… is indicated in Europe to improve walking distances in patients with intermittent claudication. It has been … failed to improve symptoms. It was contraindicated in patients with unstable angina pectoris myocardial infarction … within the last 6 months, or in patients with concomitant treatment with two or more additional antiplatelet agents …
… and disseminate your research . We'll help you increase understanding, and provide greater clarity to further reveal …
… American Society for Dermatologic Surgery Annual Meeting. Patients' willingness to accept adverse event and cost trade-offs for reduced risk of non-melanoma skin cancer. Skelsey MK, Okun MM, Schiro J, …
… properties, for at least 4 months versus no treatment on the incidence of dementia: a target trial … properties, for at least 4 months versus no treatment on the incidence of dementia: a target trial … the per-protocol effect of adhering to 3 different treatment strategies on the 12-year risk of dementia. The …